Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chart: FDA's March 2010 Clearances of 510(k)s

This article was originally published in The Gray Sheet

Executive Summary

FDA's March 2010 Clearances of 510(k)s

You may also be interested in...

New Products In Brief

Roche hepatitis C assay: Roche Diagnostics will start shipping its Elecsys Anti-HCV antibody to hepatitis C virus assay, indicated for the qualitative detection of total antibodies to hepatitis C virus in human serum or plasma, in July, the firm announced May 28. FDA granted PMA approvals for use of the test on three platforms: the stand-alone cobas e 411 analyzer for low-volume testing; and the cobas e 601 and Modular Analytics E 170 analyzers for mid- and high-volume testing, respectively. The anti-HCV assay is an 18-minute test designed for use with Roche's electrochemiluminescence technology. Roche received 510(k) clearance for another immunoassay, Rubella IgM, in April ("1The Gray Sheet" April 12, 2010)

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.

Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity

A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts